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Short Report
Enzyme replacement therapy with agalsidase
alfa in a cohort of Italian patients with
Anderson–Fabry disease: testing the effects
with the Mainz Severity Score Index
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of Italian patients with Anderson–Fabry disease: testing the effects with
the Mainz Severity Score Index.
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Anderson–Fabry disease (AFD) is a rare X-linked disorder caused by
lysosomal storage of several glycosphingolipids, affecting virtually all
organs and systems. Enzyme replacement therapy (ERT) for AFD has
been available since 2001. Due to the highly variable nature of clinical
manifestations in patients with AFD, it is very difficult to assess disease
progression and the effects of therapy. We used the Mainz Severity Score
Index (MSSI) as a measure of disease severity to study the effects of ERT
in a population of 30 patients treated with agalsidase alfa for a median of
2.9 years (range, 1.0–6.2 years). Our data show that the MSSI captures
the correlation between disease severity and both gender and age (1 –
males performing worse than females at baseline and 2 – severity of
diseases progresses with age in both sex). Furthermore, after at least
1 year of ERT, total MSSI scores were significantly lower than those at
baseline (p , 0.001), suggesting a marked clinical improvement under
ERT. In conclusion, the MSSI is a sensitive and useful tool for
monitoring disease progression and assessing the effects of ERT in
a population of patients from different treatment centres.
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Anderson–Fabry disease (AFD, OMIM 301500)
is an X-linked lysosomal storage disease that af-
fects virtually all organs and systems. It is caused
bymutations in the gene encoding a-galactosidase
A, GLA (OMIM 300644), that maps to the
Xq22 region of the X chromosome. The deficiency
of a-galactosidase A results in widespread
lysosomal storage of glycosphingolipids, mainly
1
globotriaosylceramide (Gb3) (1). AFD affects
both males and females (2, 3). The first signs and
symptoms in infancy and adolescence are neuro-
pathic and abdominal pain, cornea verticillata,
hypohidrosis, angiokeratomas, fatigue, tinnitus
and vertigo. In adulthood, vital organs such as
the kidney, heart and brain become clinically
involved, resulting in a reduced lifespan (2, 3).
Enzyme replacement therapy (ERT) became
available for AFD a few years ago, bringing about
a need for sensitive markers to the detection of the
effects of therapy. Unfortunately, at present, no
universally accepted biochemical surrogate mar-
ker has been developed for this purpose (4–6);
therefore, careful and detailed clinical and bio-
chemical monitoring of each sign and symptom
is necessary to understand disease progression
and the effects of treatment.Whybra et al. (7) have
developed a severity scoring system – the Mainz
Severity Score Index (MSSI) – that is specific for
AFD and sensitive enough to allowmonitoring of
disease progression and patients’ responses to
ERT. Although the authors concede that ‘the
MSSI probably does not always reflect true
morbidity and cannot be relied upon totally’, it
appears to be a promising tool for objectively
monitoring a wide range of signs and symptoms
in patients with AFD. To uniformly assess the
overall effects of ERT in patients with AFD, we
have calculated MSSI scores for 30 Italian pa-
tients (23 males and 7 females) at baseline and
after at least 1 year of ERT.
Patients and methods
Patients
This study was performed in four different centres
(Milano/Monza, Roma, Ortona, and Catanzaro)
and involved 30 patients with AFD, 23 males
[median age, 28.5 years (range, 4.1–47.7 years)]
and 7 females [median age, 47.7 years (range,
39.1–64.3 years)], from 16 Italian families
(Table 1). Five of 30 patients were boys between
4 and 18 years of age. A diagnosis of AFD was
confirmed by enzymatic and/or molecular an-
alysis in all subjects. ERT with agalsidase alfa
(Replagal; Shire Human Genetic Therapies,
Danderyd, Sweden) was initiated 1–40 years after
the onset of symptoms [median chronological age,
34.3 years (range, 4.1–64.3 years)]. Agalsidase
alfa was administered intravenously over a period
of 40 min at the standard dosage of 0.2 mg/kg
every other week. No serious adverse events
related to drug infusion were reported. Four male
patients had a total of 11 episodes of fever and
shivering during the infusion, occurring between
the 8th and the 18th infusion. Subsequent infusion
reactions were easily prevented by pre-treatment
with paracetamol.
Ten patients were taking non-steroidal anti-
inflammatory drugs (NSAIDs) or other medica-
tions for neuropathic pain at baseline. Other
concomitant treatments at baseline included medi-
cations for abdominal pain (antacids, n ¼ 5),
angiotensin-converting enzyme inhibitors (n ¼ 7),
calcium antagonists (n ¼ 1), diuretics (n ¼ 2),
beta-blockers (n ¼ 4) and antidepressants (n ¼ 2).
Patients continued to receive thesemedications dur-
ing ERT.Only one patient stopped takingNSAIDs
and antacids 6 months after starting ERT.
Mainz Severity Score Index
TheMSSI was used to assess overall disease sever-
ity in each patient by recording which organs or
systems were affected (7). A weighting is applied
to each affected organ depending on the antici-
pated impact of the organ’s involvement on the
overall health of the patient. For example,
involvement of the kidneys, heart and cerebrovas-
cular system has a greater impact on the total
MSSI score than involvement of the skin. The
MSSI is divided into four sections: general, neu-
rological, cardiovascular and renal. The sum of
these four scores gives the final total MSSI score.
Total MSSI scores are divided into severity bands
reflecting the clinical spectrum of the disease
(,20, mild; 20–40, moderate; and .40, severe).
For each patient, disease severity was indepen-
dently assessed by two different clinicians immedi-
ately before starting treatment and at least 1 year
after treatment had begun [median duration
of treatment, 2.9 years (range, 1.0–6.2 years)].
Neurological, cardiovascular and renal involve-
ments were assessed by the relevant specialist.
Total MSSI scores at baseline and after at least
1 year of ERT were correlated with each patient’s
age (,35 and 35 years) and sex. Changes in
MSSI scores for individual components were also
analysed.
Statistics
MSSI scores at baseline were compared with those
at follow-up by means of the Wilcoxon rank sum
test. Analyses were two-tailed, and comparisons
were considered statistically significant if p values
were below 0.05. The correlation between MSSI
score at baseline and agewas investigated bymeans
of a linear regression model, fitted in males and
females separately. R2 was calculated as a measure
of goodness of fit.
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Results
Baseline data
Total MSSI scores in the seven females ranged
from 8 to 24 (median, 16), indicating mild-to-
moderate disease involvement. In the 23 males,
scores ranged from 4 to 41 (median, 22), demon-
stratingmild involvement in 11 patients, moderate
severity in 11 patients and severe disease in 1
patient (total MSSI score, 41). A clear correlation
was found between total MSSI scores before ERT
and age in both males and females (Fig. 1). As
expected, females had lower baseline scores at
a given age than males. In male patients (plotted
by age), no correlation was found between the
severity of mutations (missense or nonsense) and
the severity of the disease.
Effects of ERT
Figure 2 shows the correlation between total
MSSI scores at baseline and after at least 1 year
of ERT (duration of treatment, 1–5 years) in
patients grouped by sex (Fig. 2a) and by age
(Fig. 2b). Patients younger than 35 years of age
had amedian change inMSSI total score of24, as
did patients equal to or older than 35 years of age,
although a more restricted range of values was
observed in the older patient group (Fig. 3).
Overall, a significant reduction in total MSSI
scores was observed across the patient cohort fol-
lowing ERT (Table 2); 22 patients improved, 4
patients had an unmodified score and 4 patients
had higher total MSSI scores after treatment.
Among the four patients with increased MSSI
scores, two boys (5 and 16 years of age) and one
woman (50 years of age) had low scores at base-
line that increased to values that were still lower
than 10 at follow-up (patients 1, 3 and 25, respec-
tively; Table 1). The remaining patient was a 53-
year-old woman treated for 4 years who had heart
surgery after 2 years of ERT (patient 26; Table 1).
The four patients who had an unmodified score
(patients 10, 14, 22 and 23; Table 1) following
treatment were all males, three of whom were
older than 35 years and had severe renal or neu-
rological symptoms.
Table 2 shows changes in MSSI scores for the
individual components (general, neurological,
cardiovascular and renal) for all 30 patients.MSSI
scores following ERT were significantly different
from those at baseline for all components, except
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Fig. 1. Total MSSI scores in males and females before
treatment vs age at start of treatment. Correlation was
determined using a linear regression model (R2 in males,
0.34 and R2 in females, 0.44). ERT, enzyme replacement
therapy; MSSI, Mainz Severity Score Index.
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renal scores. Detailed data on cardiovascular and
renal scores are shown in Table 1. Twenty-one of
30 patients had a cardiovascular MSSI score
greater than zero at baseline, decreasing to 17 pa-
tients after at least 1 year of ERT. Twelve patients
showed improved cardiovascular MSSI scores
[median change, 21 (range, 21 to 28)], three
worsened [median change, 11 (range, 11 to
15)], and six remained stable. At baseline, 19 of
30 patients had renal symptoms (renal MSSI
score, .0), 16 had microalbuminuria (albumin
excretion of 30–300 mg/day) or proteinuria (albu-
min excretion.300 mg/day) (renalMSSI score, 4),
while 3 male patients (2 renal transplanted and
1 on dialysis) had amore severe renal involvement
(renal MSSI score, 12–18). Following ERT, renal
involvement was evident in only 12 patients.
Among the 16 patients with pathologic albumin
excretion at baseline, 1 patient worsened (renal
MSSI score, 8), 8 patients remained stable (renal
MSSI score, 4), and the 7 patients who had micro-
albuminuria improved (renal MSSI score, 0).
Renal involvement in the three patients with more
severe renal damage remained unchanged follow-
ing ERT.
Discussion
We report on the effects of treatment with agalsi-
dase alfa in 30 Italian patients withAFD from four
different treatment centres, as assessed by the
MSSI (7). The MSSI was chosen as an easy instru-
ment for evaluating and comparing the clinical
effects of ERT in patients treated in different
centres. The MSSI, although not formally vali-
dated, has already been shown to be a very useful
tool for assessing disease severity in patients with
AFD (8). It has previously been shown to correlate
with age in children (9) and with serum levels of
metalloproteinase 9, which, in turn, correlates with
the severity of heart disease in patients with AFD
(10). An adapted form of the MSSI has also been
used to assess disease severity in patients enrolled in
the Fabry Outcome Survey (FOS). Using this
adaptation (FOS-MSSI), a significant correlation
with age was recently found in 262 patients, and
furthermore, patients with cutaneous vascular
lesions (CVL) were shown to have higher scores
than those without CVL (11, 12). This was ex-
pected as the presence ofCVL indicates generalized
vascular endothelial involvement.
In this study, we found a clear correlation
between total MSSI scores and age, both in males
and in females, with results very similar to those
reported byWhybra et al. (7). As a group, females
with AFD show the samemanifestations asmales,
although they typically manifest about 10 years
later (3). This is well reflected in this study in
which total MSSI scores in females parallel those
of the males who are 10–15 years younger (Fig. 1).
The reason why most heterozygous females are
symptomatic is still under discussion (13) and
cannot simply be explained by skewed X-inactiva-
tion or by the need of an elevated production of
enzyme in this disease. The recent finding of
increased concentrations of deacylated Gb3 (lyso-
globotriaosylsphingosine, lysoGb3) in plasma of
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Fig. 3. Change in total MSSI scores after at least 1 year of
enzyme replacement therapy in patients younger than
35 years of age and patients equal to or older than 35 years
of age. The box plots are drawn by age at the start of
treatment and show the mean (dot), median (rule),
interquartile range (box), and minimum and maximum
values (whiskers). MSSI, Mainz Severity Score Index.
Table 2. Change in total and individual component MSSI scores after at least 1 year of enzyme replacement therapya
n Total MSSI General MSSI Neurological MSSI
Cardiovascular
MSSI Renal MSSI
Change from
baseline
30 24 (221 to 16) 21 (25 to 13) 21 (213 to 15) 0 (28 to 15) 0 (24 to 14)
p Value — ,0.0001 0.0005 0.0056 0.0226 0.0703
MSSI, Mainz Severity Score Index.
aResults are given as median (range). The p values were determined by Wilcoxon signed-rank sum test.
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AFD male and female patients probably helps to
clarify this issue (14). LysoGb3 in fact is a potent
inhibitor of a-galactosidase A and also when it is
uptaken into cells, it is probably reacylated toGb3,
thus increasing the extralysosomal pool of Gb3,
which is not accessible to endogenous or exogenous
(ERT) a-galactosidase A. In heterozygous females
then, circulating lysoGb3 may ultimately vanish
the effects of a-galactosidase produced by
enzyme-competent cells. It has also been shown
that lysoGb3 is probably directly implicated in
the development of the disease as it has an effect
of stimulation of vascular remodelling (14).
Overall, a significant reduction in total MSSI
scores was observed across the patient cohort fol-
lowing ERT (Table 2). This is in agreement with
the literature as the clinical benefit of ERT has
been demonstrated in both placebo-controlled tri-
als and open-label observational studies (15–20).
A certain number of patients treated with agalsi-
dase alfa or agalsidase beta have previously been
reported to show no response to ERT (15, 16, 20).
In some patients, this may be attributed to exces-
sively advanced disease, although not in all cases.
Improvements in total MSSI scores in our group
of patients were mainly due to changes in general
and neurological components, while heart and
renal involvement showed milder improvements.
Detailed analysis of our data shows that 21 of 30
patients had heart involvement and 19 had renal
involvement at baseline. The vast majority of
these patients exhibited an improvement or
stabilization of cardiac or renal involvement
after ERT. Given the progressive nature of
AFD, stabilization can be seen as a positive out-
come following treatment. The fact that, prior to
ERT, MSSI scores for heart and renal compo-
nents were 0 for 9 and 11 patients, respectively,
may explain why the differences between pre-
and post-treatment scores are weakly significant
for cardiovascular involvement and not signifi-
cant for renal manifestations.
The benefits of ERT with agalsidase alfa are
clear in the majority of our patients who showed
reduction of pre-existing pain, hypohidrosis,
auditory and gastrointestinal symptoms, and an
improvement or stabilization of renal and cardiac
signs. While we can confirm that treatment with
agalsidase alfa was beneficial in most of our
patients, our data show how unpredictable the
evolution of the disease can be in individual
patients receiving treatment.
There are reasons for a critical use of MSSI
because it certainly does not completely reflect
true morbidity: firstly, it was developed when
not all signs and symptoms of the disease (e.g.
haematuria and hearing deficiency) had been fully
investigated and secondly, it is surely a more
convenient instrument for the classic Fabry
patient presenting the whole spectrum of symp-
toms than formono- or oligosymptomatic females
or children who do not have major organ involve-
ment. So, on this basis, minormodifications of the
MSSI in the near future may be conceivable.
Nonetheless, theMSSI as it is at present is a useful
instrument to test patients withAFDand sensitive
enough to show the expected increase in severity
by age, the differences in severity by gender and
the improvement of symptoms due to at least
1 year of ERT. In our population of 30 patients,
it allowed us to objectively and homogeneously
measure the clinical status of patients from four
different centres.
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